Onconova Flash Banner
Welcome
Onconova Therapeutics is developing new drugs for treating cancer and radiation injury.
Onconova's anti-cancer drugs are targeted therapies that exploit differences in cell cycle regulation of normal versus cancer cells. They are designed to address three major problems associated with current cancer medicines by:
- Improving efficacy
- Overcoming drug resistance
- Relieving the burden of toxicity
The Company's lead radiation protection agent reduces the damaging effects of radiation exposure by enhancing cell survival and DNA repair pathways.
Onconova has three clinical-stage products in Phase I and Phase II trials, several pre-clinical product candidates, more than 100 issued patents, and a focused internal R&D engine.
HIGHLIGHTS
- ON 01910.Na, Onconova's most advanced anti-cancer agent, is in Phase II studies; the first clinical indication is for treating patients with myelodysplastic syndromes (MDS). Additional hematologic and solid tumor indications are being developed, both as single agent and in combination therapy.
- Ex-RADTM is in Phase I clinical testing in healthy volunteers to support approval as a radiation protection agent. Ex-RADTM is being developed under guidance of the FDA's "Animal Rule".
- ON 013105, a new anti-cancer drug that targets cyclin D1 over-expression, has entered the clinic for proof-of-principle trials in lymphoma.